ADMET Optimization

ADMET optimization applies the same structure-driven design strategies used for potency optimization to the systematic improvement of a compound's...

ADMET optimization applies the same structure-driven design strategies used for potency optimization to the systematic improvement of a compound's absorption, distribution, metabolism, excretion, and toxicity profile, recognising that a substantial proportion of drug candidates historically failed in development not for lack of potency but because of unfavourable ADMET behaviour identified only after considerable resource had already been invested. Contemporary lead optimization integrates ADMET assessment from the earliest optimization rounds rather than deferring it to a late-stage, isolated evaluation, using the in-silico and in-vitro ADMET prediction tools described in Phase 1 to flag emerging liabilities — declining metabolic stability, an emerging hERG channel binding risk, or a structural alert associated with genotoxicity — early enough that the responsible structural feature can still be addressed through further chemical modification rather than forcing the abandonment of an otherwise promising chemical series.